M., F., Y., W., S., T., P., S., S., L., V., S., . . . N., S. (2017). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS).
Chicago Style CitationM., Fukuoka, et al. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-label, First-line Study of Gefitinib Versus Carboplatin/paclitaxel in Clinically Selected Patients With Advanced Non - Small-cell Lung Cancer in Asia (IPASS). 2017.
MLA CitationM., Fukuoka, et al. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-label, First-line Study of Gefitinib Versus Carboplatin/paclitaxel in Clinically Selected Patients With Advanced Non - Small-cell Lung Cancer in Asia (IPASS). 2017.